RxDoctor Payments Data

Xavier Ng, MD

Physical Medicine & Rehabilitation · Park City, KSNPI 1265530182

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Pfizer at 38.8% of the total.

$520in general payments, 2019–2025

Across 34 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$202
  • Electronic Waveform Lab, Inc.$117
  • Kaleo, Inc.$96
  • Sentynl Therapeutics, Inc.$51
  • Collegium Pharmaceutical, Inc.$42
  • Boston Scientific$12

What the payments were for

  • Food & beverage$520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer22$202
Electronic Waveform Lab, Inc.2$117
Kaleo, Inc.2$96
Sentynl Therapeutics, Inc.4$51
Collegium Pharmaceutical, Inc.3$42
Boston Scientific1$12

How this compares

$520 in reported general payments places this provider in the 60th percentile of 80 physical medicine & rehabilitation providers in Kansas.

See all physical medicine & rehabilitation providers in Kansas

Medicare billing

Part B allowed, 2024
$96,222
Medicare patients
171
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl50$46,578
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen961$22,449
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen753$20,382
Oxycodone Hcl1,210$19,527
Pregabalin493$9,287
Gabapentin552$9,027
Xtampza ErOxycodone Myristate25$6,511
MovantikNaloxegol Oxalate13$6,273
Morphine Sulfate ErMorphine Sulfate320$5,675
Morphine Sulfate324$4,952
Fentanyl80$4,650
Doxepin Hcl143$4,620
Trazodone Hcl458$4,556
Hydromorphone Hcl380$3,979
Tizanidine Hcl280$3,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$42$6,51125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 80 physical medicine & rehabilitation providers in Kansas.

Other physical medicine & rehabilitation in Park City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →